Hims stock crumbled Tuesday after the telehealth platform issued a lackluster outlook for the current three-month period, despite beating first-quarter sales expectations.
For the second quarter, Hims & Hers Health (HIMS) guided to $530 million to $550 million in sales. Analysts were expecting $565 million, according to FactSet.
↑
X
The Weight-Loss Drug Market Is Hot. Which Medical Stock Will Win The Battle For Supremacy?
In response, Hims stock skidded more than 7% to 38.68 in early trades on today’s stock market. If the move holds, Hims shares will open above their 50-day moving average, MarketSurge shows.
Hims Stock Dives On Mixed Report
Overall, the first quarter came out mixed. Hims & Hers earned an adjusted 20 cents per share. That missed expectations for 24 cents, but quadrupled year over year. The company also reported $586 million in sales, beating forecasts for $539 million. Sales skyrocketed 111% vs. the year-ago period.
Promisingly, Hims & Hers reported 38% growth in monthly subscribers to nearly 2.4 million. Each subscriber pays $84 a month, which is up 53% vs. the same three months in 2024.
The news comes shortly after Hims inked a deal with Novo Nordisk (NVO) to sell Wegovy on its telehealth platform in conjunction with a Hims membership for $599 a month. Hims stock shot up 23% on April 29 following the announcement.
“Over time, we expect wider collaboration across the industry, inclusive of pharmaceutical players, innovative leaders in diagnostic and preventative testing, and world class providers,” Hims Chief Executive Andrew Dudum said in a written statement. “We believe this will strengthen our ecosystem and position us to curate a best-in-class offering that can reach tens of millions of people.”
Long-Term Outlook
For the year, Hims & Hers guided to $2.3 billion to $2.4 billion in sales. The company also introduced its long-term outlook for $6.5 billion in revenue and $1.3 billion in adjusted earnings before interest, taxes, depreciation and amortization by 2030.
Shares have a perfect IBD Digital Composite Rating of 99. This means Hims stock is outperforming 99% of all stocks when it comes to fundamental and technical measures. Shares also have a strong Relative Strength Rating of 98, a measure of 12-month performance.
Follow Allison Gatlin on X/Twitter at @AGatlin_IBD.
YOU MAY ALSO LIKE:
IBD 50’s GeneDx, Down 39%, Was ‘Priced For Perfection.’ Here’s What It Missed.
S&P 500 Stock Pfizer Jumps As Cost-Cutting Bolsters Profit
See Stocks On The List Of Leaders Near A Buy Point
How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks
